



EURE-CART Project: the members of the EURE-CART's Consortium gather in Lisbon for the 2nd General Assembly. EURE-CART focuses on the study of the antitumor immunotherapy with CD44v6 CAR-T cells

Lisbon, 21 March 2018 – The EURE-CART Consortium announces the second General Assembly Meeting of the EURE-CART Project (EUROpean Endeavour for Chimeric Antigen Receptor Therapies) today in conjunction with the annual meeting of the 44th EBMT (European Society for Blood and Marrow Transplantation).

The project, which started in 2017, has been financed by the European Research and Innovation Programme "Horizon 2020" with a EUR 5.9 million grant and brings together experts in onco-haematology and above all internationally recognised leaders in the field of Cell & Gene therapy, with the main objective to confirm cell therapy based on CAR-T lymphocytes as a personalised treatment capable of defeating neoplastic diseases.

In particular, the goal of the project is to conduct the first multi-center clinical trials Phase I/II in humans, aimed at demonstrating the safety and efficacy of immunotherapy based on T lymphocytes genetically modified with a chimeric

EURE- CART HAS RECEIVED FUNDING FROM THE EUROPEAN UNION'S HORIZON 2020 RESEARCH AND INNOVATION PROGRAMME UNDER THE GRANT AGREEMENT NO. 733297

specific receptor (CAR) for the CD44v6 antigen (CD44v6 CAR-T), in patients with acute myeloid leukemia (AML) and multiple myeloma (MM), populations with an overexpression of this antigen up to 80% of AML cells and 90% of MM cells respectively.

The CD44v6 CAR-T used for the trials are lymphocytes that have demonstrated great antitumor potential, thanks to their ability to specifically recognize variant 6 (v6) of the CD44 antigen (CD44v6), expressed not only by many haematological malignancies, but also by many epithelial tumours, including breast, colon, pancreas, head/neck and lung carcinomas. Their production will take place at the MolMed S.p.A. facility.

The EURE-CART Consortium consists of representatives of nine Partners from four different European Union countries¹ with excellent clinical, scientific and industrial skills in their respective areas of competence. They are led by the Italian Company MolMed S.p.A., Coordinator of the project thanks to its own track record in the field of gene and cell therapy. The Consortium meets annually in the General Assembly to discuss, plan and evaluate both the progresses achieved and the future programs within the ongoing research project.

"During the work of the Lisbon's Assembly we shared the updates of the activities carried out so far in the various centres and planned the next steps

¹ Ospedale San Raffaele S.r.l. (Italy), Universitätsklinikum Würzburg (Germany), Ospedale Pediatrico Bambino Gesù (Italy), Fundacio Privada Institut de Recerca de L'hospital de la Santa Creu i Sant Pau (Spain), Fakultni Nemocnice S Poliklinikou Ostrava (Czech Republic), Istituto Superiore di Sanità (Italy), Acromion GMBH (Germany), ARTIC SAS (Germany)

of the coming months" explains Catia Traversari, Scientific Head of EURE-CART and Research Director of MolMed. "In particular, since we aim at starting the experimentation in humans of our CAR-T, we focused on the finalisation of the clinical protocol and on the action plan for the first study planned to start in 2018".

The EURE-CART project will develop its activities within 48 months from its start date, on 1 January 2017, and foresees also the active involvement of National Regulatory Authorities to accelerate the approval of this specific immunotherapy with CAR-T cells.

For further information:
<http://www.eure-cart.eu/>

twitter: [@EURECART_EU](https://twitter.com/EURECART_EU)



EURE- CART HAS RECEIVED FUNDING FROM THE EUROPEAN UNION'S HORIZON 2020 RESEARCH AND INNOVATION PROGRAMME UNDER THE GRANT AGREEMENT NO. 733297

EURE- CART HAS RECEIVED FUNDING FROM THE EUROPEAN UNION'S HORIZON 2020 RESEARCH AND INNOVATION PROGRAMME UNDER THE GRANT AGREEMENT NO. 733297